Roundtable Discussion: Novel Oral Anti-Coagulants (NOACs)

On November 12th 2014, Radcliffe Cardiology, in association with the Arrhythmia & Electrophysiology Review (AER) journal, filmed a roundtable discussion entitled 'Novel Oral Anti-Coagulants (NOACs): Hot Topics & Current Issues' in London, UK.

The discussion was moderated by Professor A. John Camm (London, UK), a renowned authority in anticoagulation and atrial fibrillation, and an editorial board member of AER. He was joined by expert group of physicians including Doctor Marco Alings (Breda, NL), Professors Raffaele De Caterina (Chieti, IT), Paulus Kirchhof (Birmingham, UK), Jean-Yves Le Heuzey (Paris, FR) and Freek Verheugt (Amsterdam, NL).

The meeting comprised of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants in various clinical scenarios.

This educational activity is intended for an international audience of non-US healthcare professionals, specifically electrophysiologists and cardiologists. However, neurologists, internal medicine specialists, primary care physicians, and other healthcare professionals involved in the diagnosis and management of patients with atrial fibrillation (AF) will also find this topical.

The CME e-learning modules can be accessed here. This course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 CME credit hour.

On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulation and atrial fibrillation. The meeting comprised a series of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants (NOACs): real-world versus clinical trial data; once or twice daily dosing regimens; spot checks or monitoring for anticoagulation status; antidotes for NOACs; NOACs and dual antiplatelet therapy; NOAC treatment in chronic renal impairment; and choosing between NOACs. This paper summarises the presentations and presents key highlights from the subsequent discussions.